This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
University of Connecticut, 2007.). Oncologists have told us, in research, that they would like more resources to give to patients to start chemo so they better understand exactly what’s happening and what they can do to minimize sideeffects. economy up to $236 billion every year. Trujillo, S. Rosenbaum, and B.
Professional Advertising: Professional advertising, also known as Direct-to-Professional (DTP) advertising, is another type of pharmaceutical advertising that is aimed at healthcare professionals such as doctors, nurses, and pharmacists. “Pharmaceutical Advertising: A Guide for Healthcare Professionals.” Sources: 1.
Demand for treatment The American Cancer Society estimates that over 12 million new cancer cases were diagnosed worldwide in 2007. “There’s a huge clinical need which has been undelivered for years,” says Gustav Ando, manager of the healthcare business development unit [HBDU] at Global Insight.
Additionally, EURneffy could alleviate the risk of accidental needle-related sideeffects (such as injection into the blood vessel and hand) 3 and it has the attributes of being smaller in size, has better temperature sensitivity, and is less complex to use compared to needle-based injectors. .” 2007; 2(1):5-11.
NB: Recent figures show the pharmaceutical industry spent $168m lobbying congress in 2007, how successful were the industry’s efforts and what are the main administration issues concerning the industry at present? So far I don’t think the FDA has approved any trials evaluating stem cells in humans.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content